Trump Endorses Medical Cannabis as 'Best Alternative' for Patients

President Donald Trump offered his strongest public endorsement yet of medical marijuana Thursday, calling it "the best of all the alternatives" for people dealing with serious health conditions.

"A lot of people are suffering from big problems, which this seems to be the best answer," Trump told reporters in the Oval Office. "They're very happy about it."

The comments came just hours after the Department of Justice announced it would move forward with a proposal to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act—a shift that would acknowledge the plant's medical value for the first time at the federal level.

The Timing

Trump's remarks represent a notable evolution in presidential rhetoric on cannabis policy. While he's previously expressed support for state-level medical marijuana programs, Thursday's comments arrived at a crucial juncture in federal cannabis reform.

The DOJ's rescheduling announcement follows a lengthy review process initiated by the Biden administration in 2022. Moving cannabis to Schedule III would maintain federal prohibition but ease research restrictions and potentially provide tax relief for state-legal cannabis businesses currently barred from standard deductions under 280E.

But the president's framing—positioning medical marijuana as superior to other treatment options—goes beyond typical political support for reform. It suggests an administration potentially willing to defend expanded medical access as rescheduling faces inevitable legal challenges.

Industry Response

Cannabis industry advocates have long argued that federal policy lags behind both scientific evidence and public opinion on medical marijuana. Thirty-eight states now permit medical cannabis programs, with conditions ranging from chronic pain to PTSD to epilepsy.

The medical cannabis market generated an estimated $8.4 billion in sales last year, according to industry analytics firms. Patient advocates have pushed for years to expand access and remove federal barriers to research—barriers that Schedule I classification has maintained since 1970.

Trump's comments may signal broader White House support for medical cannabis that could influence how the rescheduling process unfolds. The proposal must still navigate a public comment period and potential legal challenges from both reform advocates (who want full descheduling) and opposition groups.

What Happens Next

The rescheduling timeline remains uncertain. After DOJ formally submits its proposal, federal agencies will accept public comments before finalizing any rule change. That process typically takes months, though the administration could attempt to expedite it.

Meanwhile, Trump's medical marijuana endorsement raises questions about his position on broader adult-use legalization. During his first term, he expressed support for states' rights on cannabis policy but didn't push comprehensive federal reform. His administration also rescinded Obama-era guidance that had discouraged federal enforcement in legal states.

The president didn't elaborate Thursday on which specific conditions or treatments he was referencing, nor whether his support extends beyond medical use. But for an industry long accustomed to federal ambivalence at best, a sitting president calling cannabis "the best answer" for suffering patients marks a significant rhetorical shift—one that arrives precisely as federal policy stands poised for its most substantial change in half a century.

This article is based on original reporting by www.marijuanamoment.net.